This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There’s new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.
Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
Purified Cortrophin Gel is a purified adrenocorticotropic hormone.
The prescribing information for the product has been updated to include this health related outcome.
Given that treatment options for RA are rapidly changing, the study authors aimed to summarize information surrounding potential drug-drug interactions with JAK inhibitors in order to help health care providers make informed decisions.
WellDyne will provide physicians access to Scipher Medicine’s PrismRA test, which identifies RA patients unlikely to respond to TNFi therapy.
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
